Soluble ST2 and the course of lung injury in ARDS
Official title: The Impact of Soluble ST2 on Lung Injury Onset and Resolution
Funded at Massachusetts General Hospital · NIH-11631207 · Data updated 2026-11-12
A doctor-scientist at a top hospital is studying how a molecule called soluble ST2 may influence how lung injury starts and heals in patients with ARDS and related conditions.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $58,320 |
| NIH project number | 3K08HL173572-03S1 |
| Project ID | NIH-11631207 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with ARDS or acute lung injury who are undergoing care in hospital settings and whose data or samples could contribute to longitudinal analyses.
✕Less likely to help
During the study, some patients may not directly benefit if findings do not translate to clinical practice or if they are not enrolled in any associated trials.
What this research studies
This grant funds training for Dr. Jehan Alladina to work on mouse models of acute lung injury and to analyze patient data over time, with the aim of understanding how T2 immune responses affect ARDS progression and recovery. The program combines hands-on experiments in animals, advanced statistics to track disease trajectories, and translational research to connect findings to humans. The trainee will receive mentorship from lung immunology and biostatistics experts and will take coursework in immunology and translational sciences. The long-term goal is to build an independent research program focused on the immune processes that drive lung injury and healing in ARDS.
Why it matters
Potential benefit: If successful, this work could reveal new targets to modulate immune responses in ARDS, potentially improving recovery and outcomes for patients.
How similar studies have gone: Prior work in ARDS and immune pathways suggests that immune responses influence outcomes, but translating findings to therapies remains an active area of research.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Alladina, Jehan — Massachusetts General Hospital
- Study coordinator: Alladina, Jehan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.